Merck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy Merck…

Read MoreMerck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Global Cell Freezing Media Market to Reach $291.3 Million by 2030 – Driven by Rising Adoption of Ready-to-Use Freezing Media – ResearchAndMarkets.com

Global Cell Freezing Media Market to Reach $291.3 Million by 2030 – Driven by Rising Adoption of Ready-to-Use Freezing Media – ResearchAndMarkets.com The “Cell Freezing Media Market Size, Share & Trends…

Read MoreGlobal Cell Freezing Media Market to Reach $291.3 Million by 2030 – Driven by Rising Adoption of Ready-to-Use Freezing Media – ResearchAndMarkets.com

Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics

Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics Biomedicines, a clinical-stage biotherapeutics company pioneering a machine-learning-powered generative biology…

Read MoreBiomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics

RS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability

RS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability RS Oncology , a clinical-stage biotechnology company developing innovative therapies…

Read MoreRS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability

Ahead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity

Ahead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity Ahead of discussions at the United Nations General Assembly (UNGA78),…

Read MoreAhead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity

IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry

IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry IRLCA und EAD haben die Grundlage für eine bahnbrechende Zusammenarbeit gelegt, die regulatorische Compliance…

Read MoreIRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry